Is Wanbury a good stock to invest in?

Wanbury can be analyzed on the following key metrics - TTM P/E: 25.13 Sector P/E: 22.43 Dividend Yield: 0% D/E ratio: -

Wanbury Share Price

Sector: Biotechnology & Drugs

Powered by

285.20 +9.80 (3.56%)

1D
5D
1M
3M
6M
1Y
5Y
MAX

Price Range

Today’s Low 274.00

Today’s High 286.55

52 Week Low 151.10

52 Week High 330.00

Key Metrics

Market Cap (In Cr) 935.97
Beta 1.29
Div. Yield (%) 0
P/B 15.69
TTM P/E 25.13
Sector P/E 22.43
D/E 0.03
Open Price 275
Prev Close 275.4

View All Metrics

Wanbury Analysis

Price Analysis

1 Week

2.29%
3 Months

21.02%
6 Month

1.12%
YTD

-2.57%
1 Year

81.5%

Risk Meter

63% Low risk
63% Moderate risk
63% Balanced Risk
63% High risk
63% Extreme risk

Wanbury News

From ₹19 to ₹299, this stock soars 1475% in 5 years; Ventura sees another 53% upside (Pixabay)

Premium

From ₹19 to ₹299, this stock soars 1475% in 5 years; Ventura sees 53% upside

2 min read . 13 Jun 2025

Premium

Wanbury Q4 Results Live : profit rise by 3211.99% YOY

1 min read . 19 May 2024

Premium

Wanbury Q3 FY24 results: profit at ₹10.27Cr, Revenue increased by 15.68% YoY

1 min read . 27 Jan 2024

Premium

Wanbury PAT up 150% at Rs9 crore

1 min read . 02 Nov 2007

View More News

Wanbury Financials

INCOME
BALANCE SHEET
Cashflow

DATE

Annual

Quarterly

Period
2025

Total Revenue
599.51

Selling/ General/ Admin Expenses Total
104.24

Depreciation/ Amortization
13.31

Other Operating Expenses Total
124.49

Total Operating Expense
536.51

Operating Income
63.01

Net Income Before Taxes
29.55

Net Income
30.53

Diluted Normalized EPS
8.98

Period
2024

Total Revenue
575.65

Selling/ General/ Admin Expenses Total
168.95

Depreciation/ Amortization
13.03

Total Operating Expense
490.18

Operating Income
85.47

Net Income Before Taxes
56.34

Net Income
55.96

Diluted Normalized EPS
9.16

Period
2023

Total Revenue
499.65

Selling/ General/ Admin Expenses Total
152.57

Depreciation/ Amortization
12.38

Total Operating Expense
488.72

Operating Income
10.93

Net Income Before Taxes
-10.29

Net Income
-10.4

Diluted Normalized EPS
-3.05

Period
2022

Total Revenue
511.19

Selling/ General/ Admin Expenses Total
74.81

Depreciation/ Amortization
11.45

Other Operating Expenses Total
100.77

Total Operating Expense
410.96

Operating Income
100.23

Net Income Before Taxes
81.13

Net Income
81.47

Diluted Normalized EPS
9.85

Period
2021

Total Revenue
392.52

Selling/ General/ Admin Expenses Total
64.15

Depreciation/ Amortization
9.75

Other Operating Expenses Total
93.2

Total Operating Expense
384.25

Operating Income
8.27

Net Income Before Taxes
-12.41

Net Income
-12.61

Diluted Normalized EPS
-5.04

Period
2020

Total Revenue
367.45

Selling/ General/ Admin Expenses Total
67.48

Depreciation/ Amortization
9.68

Other Operating Expenses Total
100.79

Total Operating Expense
353.69

Operating Income
13.76

Net Income Before Taxes
64.67

Net Income
64.46

Diluted Normalized EPS
4.46

Period
2019

Total Revenue
391.37

Selling/ General/ Admin Expenses Total
179.3

Depreciation/ Amortization
9.97

Total Operating Expense
385.46

Operating Income
5.91

Net Income Before Taxes
-24.98

Net Income
-24.85

Diluted Normalized EPS
-10.38

View detailed financials

Forecast

Income Sheet (In Cr) Net Income Vs Revenue

Returns Metrics (In Cr) ROA Vs ROE

Forecast

Balance Sheet Asset vs Liability

Forecast

Cash Flow Operating vs Investing

Wanbury Technical

Moving Average SMA

5 Day275.82
10 Day288.45
20 Day292.27

50 Day277.14
100 Day248.74
300 Day251.46

Wanbury Peers

Price
Ratio

Name
Latest Price
Change
% Change
52W High
52W Low
Mkt. Cap

Aayush Wellness
198.95
3.9
2
195.05
16.8
968.32

Fermenta Biotech
323.55
6.3
1.99
449
163
952.24

Wanbury
285.2
9.8
3.56
330
151.1
935.97

Kopran
185.55
0.55
0.3
369.2
157
898.85

Shree Ganesh Remedies
601.95
-9.8
-1.6
950.05
600
771.03

Wanbury Shareholding

Shareholding Pattern

*Promoter pledging: 30.51%

Shareholding Trend

Shareholding(%) v/s Date

View All

Corporate Actions

Board Meeting
AGM
Dividends
Bonus
Split
Rights

Meeting Date
Purpose

15-May-25
Audited Results

12-Feb-25
Quarterly Results & Others

13-Nov-24
Quarterly Results

12-Aug-24
Quarterly Results

16-May-24
Audited Results

24-Jan-24
Quarterly Results

20-Oct-23
Quarterly Results & Preferential issue

11-Aug-23
Quarterly Results

09-Jun-23
Audited Results

30-May-23
Audited Results

Meeting Date
Announced on
Purpose

20-Feb-25
24-Jan-25
EGM

27-Sept-24
17-Sept-24
AGM

18-Nov-23
26-Oct-23
EGM

27-Sept-23
18-Sept-23
AGM

21-Aug-23
20-Jul-23
EGM

28-Sept-22
22-Jun-22
AGM

17-Mar-22
23-Feb-22
EGM

20-Mar-21
23-Feb-21
EGM

View All

Company Profile

ABOUT Wanbury

Industry Biotechnology & Drugs
ISIN INE107F01022
BSE Code 524212
NSE Code WANBURY

Wanbury Limited is an India-based pharmaceutical company with a presence in the active pharmaceutical ingredients (APIs) global market and domestic branded formulations. The Company is engaged in the business of pharmaceutical and related activities, including research. Its API products include Metformin, Metformin Dc, Tramadol, Sertraline, Diphenhydramine HCL, Diphenhydramine Citrate, Mefenamic Acid, Paroxetine Hemihydrate, Promethazine, Glucosamine, Clopidogrel, Levetiracetam and Carvedilol Phosphate Monohydrate. In formulations, the Company has a presence across various therapeutic categories, such as cough and cold solutions, gynecology, orthopedics, nutraceuticals, gastrointestinal, anti-inflammatory and analgesics. The Company is also focused on the development of products like ketamine, rivaroxaban, montelukast, sitagliptin and a few others to reduce dependency on metformin and sertraline. The Company has facilities in Tanuku, Andra Pradesh, and Patalganga, Maharashtra.

MANAGEMENT

K. Chandran Vice Chairman of the Board
Vinod Verma Chief Financial Officer
Jitendra Gandhi Compliance Officer, Company Secretary

WANBURY SUMMARY

Wanbury is trading 3.56% upper at Rs 285.20 as compared to its last closing price. Wanbury has been trading in the price range of 286.55 & 274.00. Wanbury has given -2.57% in this year & 2.29% in the last 5 days.

Wanbury has TTM P/E ratio 25.13 as compared to the sector P/E of 22.43.

The company posted a net profit of 20.26 Crores in its last quarter.

Listed peers of Wanbury include Aayush Wellness (2%), Fermenta Biotech (1.99%), Wanbury (3.56%) etc.

Wanbury has a 39.76% promoter holding & 60.24% public holding.

FAQs about Wanbury

Wanbury is trading at 285.20 as on 27 Jun, 2025 3:45:38 PM. This is 3.56% upper as compared to its previous closing price of 275.4

The market capitalization of Wanbury is 935.97 Cr as on 27 Jun, 2025 3:45:38 PM.

The 52 wk high for Wanbury is 330.00 whereas the 52 wk low is 151.10

Wanbury can be analyzed on the following key metrics -

TTM P/E: 25.13
Sector P/E: 22.43
Dividend Yield: 0%
D/E ratio: -

Wanbury reported a net profit of 30.53 Cr in 2025.

Wanbury Quick Links

Equity Quick Links

Top Gainers | Top Losers | Indian Indices | BSE Active Stocks | NSE Active Stocks

Wanbury Share Price

Price Range

Price Range

Key Metrics

Wanbury Analysis

Wanbury News

From ₹19 to ₹299, this stock soars 1475% in 5 years; Ventura sees 53% upside

Wanbury Q4 Results Live : profit rise by 3211.99% YOY

Wanbury Q3 FY24 results: profit at ₹10.27Cr, Revenue increased by 15.68% YoY

Wanbury PAT up 150% at Rs9 crore

Wanbury Financials

Forecast

Forecast

Forecast

Wanbury Technical

Wanbury Peers

Wanbury Shareholding

Shareholding Pattern

Shareholding Trend

Corporate Actions

Company Profile

ABOUT Wanbury

MANAGEMENT

WANBURY SUMMARY

FAQs about Wanbury

Wait for it…

Wait for it…

Congratulations!

Subscribe to continue